‣ Participants must meet all inclusion criteria to be eligible for trial participation.

• Males or females ≥ 50 years of age at the time of signing the informed consent.

• Diagnosis of HFpEF as defined by European Society of Cardiology or American College of Cardiology/American Heart Association criteria

• NYHA Functional Class II or III

• LVEF ≥ 50% demonstrated by echocardiography (ECHO) performed at Screening and evidence of heart failure with history of at least one HF hospitalization

• Elevated NT-proBNP at Screening

• NordicPRO-C6™ ≥ 11 ng/mL at Screening.

• Stable dose of all concomitant HF medications for at least 4 weeks prior to Screening.

• Body weight of at least 110 lbs (50 kg) and body mass index (BMI) within the range ≥ 18 to \< 45 kg/m2.

• Males must agree to the contraception requirements and females must be of non-childbearing potential

⁃ Able to understand and willing to sign a written informed consent form (ICF).

⁃ Willing and able to comply with trial procedures and restrictions listed in the ICF and in this protocol.